Bioliberty Raises $10.2M for AI Rehab Technology

Healthtech innovator Bioliberty has successfully closed a significant funding round, amassing $10.2 million to accelerate the development and deployment of its advanced functional intelligence solutions for post-acute care. This capital infusion, comprising a $8.2 million Series A and a prior $2 million pre-Series A, signals strong investor confidence in the company's mission to revolutionize physical and occupational therapy.

The Series A round was spearheaded by a substantial $4 million commitment from the Scottish National Investment Bank, a key backer of Scottish enterprises. The investment was further bolstered by continued support from existing stakeholders, including Archangels, Eos Advisory, Old College Capital, and Hanna Capital SEZC. Notably, Conduit Connect also joined as a new investor, underscoring the growing appeal of Bioliberty's technology in the competitive healthtech arena.

Bioliberty's core offering revolves around its AI and robotics-powered platform designed to meticulously monitor patient recovery and enhance the delivery of intensive therapy. Its flagship product, Lifehub Clinic, is already making inroads in U.S. post-acute care facilities, demonstrating impressive clinical adoption. The company's technology is currently utilized by several major U.S. post-acute care providers, including partnerships with the third-largest rehabilitation provider nationally and the Sheltering Arms Institute.

The newly acquired capital will be instrumental in refining the Lifehub Clinic platform, integrating cutting-edge computer vision and care coordination features. Crucially, the funding will also fuel the commercial rollout of Lifehub Home, a complementary system aimed at extending therapeutic monitoring and progress tracking directly into patients' residences following their discharge from clinical settings. This dual-pronged approach addresses the critical need for continuous care and data-driven insights throughout the recovery journey.

The post-acute care sector is grappling with significant workforce shortages and an increasing demand for improved patient outcomes. Bioliberty's functional intelligence platform directly confronts these challenges by bridging the gap between specialized clinical expertise and scalable technological solutions. The company, which has raised a cumulative $17.5 million since its 2023 seed round, is strategically positioned to address these market imperatives.

With dual headquarters in Edinburgh and Boston, Bioliberty is well-placed to leverage its European innovation base while aggressively scaling its U.S. operations. The Scottish National Investment Bank's backing highlights its commitment to fostering growth in the healthtech sector and supporting companies with global ambitions. The company's CEO, Rowan Armstrong, expressed optimism regarding the platform's initial success in the U.S., emphasizing its positive impact on patient recovery metrics.